White & Case, Paul, Weiss, Rifkind, Wharton & Garrison and Ritch Mueller advised on the deal
Sanfer, one of Mexico’s leading independent pharmaceutical companies, has obtained a USD $500 million minority investment from Caisse de dépôt et placement du Québec (CDPQ), a long-term institutional investor. The investment, one of the largest minority private equity transactions in Mexico, will enable Sanfer to execute on its continued expansion plans across Mexico and the broader Latin American region.
Over the past two decades, Sanfer has had a longstanding commitment to offering innovative and high-quality pharmaceutical products to its customers. Over this period, the Company has closed over 100 brand acquisitions, acquired 8 pharmaceutical companies and launched over 100 new products across Mexico and Latin America. Sanfer intends to use this new capital to accelerate its growth, both organic and through further acquisitions, across the region.
Sanfer is a leading Mexican pharmaceutical company with presence in over 25 countries across Latin America.
INVEKRA was founded in Mexico with the aim to consolidate the controlling interest of Laboratorios Sanfer and Laboratorios Hormona. NVEKRA currently employs more than 2,900 people working as operators, managers, technicians and specialists in 10 Latin American countries. Day by day, we put special care in every detail so as to manufacture top-quality products and be able to offer them to prescribers and consumers in a timely and proper fashion.
White & Case LLP advised CDPQ.
Paul, Weiss, Rifkind, Wharton & Garrison LLP advised General Atlantic in US.
Ritch Mueller advised Invekra and General Atlantic with Luis A. Nicolau Gutiérrez (Picture), Gabriel Robles Beistegui and Tomás Antonio Bayo Canalizo.
Law Firms: Ritch, Mueller, Heather y Nicolau, SC;